Argentina Rejects Key Sofosbuvir Patent Application
Executive Summary
Argentina’s patent office, INPI, has rejected an application for a key patent relating to Gilead’s hepatitis C drug Sovaldi (sofosbuvir).
You may also be interested in...
Brazil Prepares To Make Its Own Sovaldi As Regulator Opposes Patent Application
Brazil could soon be manufacturing its own generic version of Gilead’s Sovaldi if opposition to the company’s patent application is upheld by the patent office.
Fresh EU-Wide Challenge To Sovaldi Patent Puts The Spotlight On Drug Pricing Again
Access to affordable medicines has become a global challenge. A new chapter has been added to the struggle as several EU-based civil society groups join hands to challenge Gillead’s sofosbuvir patent in a bid to increase access to affordable hepatitis C treatment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.